News

All Articles

Filter by year:

Helius Medical Technologies and HealthTech Connex Announce Exclusive Distribution Agreement for the Portable Neuromodulation Stimulator (PoNS®) Device

March 22, 2023

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results

March 9, 2023

Helius Medical Technologies Announces Authorization from Health Canada to Market Portable Neuromodulation Stimulator (PoNS®) Device for the Treatment of Gait Deficit Due to Mild and Moderate Symptoms from Stroke

March 9, 2023

Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023

March 6, 2023

Helius Medical Technologies to Present at the 35th Annual ROTH Conference

March 2, 2023

Helius Medical Technologies to Showcase PoNS Therapy™ at American Physical Therapy Association’s 2023 Combined Sections Meeting

February 15, 2023

Helius Medical Technologies, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2022

January 23, 2023

Helius Medical Technologies to Present at the Virtual Q1 Investor Summit Microcap Event, January 26, 2023

January 19, 2023

Helius Medical Technologies, Inc. Announces Participation of Neurology Center of New England in its Therapeutic Experience Program

January 10, 2023

Helius Extends its Patient Therapy Access Program (PTAP), Bringing the Benefits of its PoNS® Device to More People with Multiple Sclerosis

January 5, 2023

Helius Launches UpScript Telehealth e-Commerce Site, Making it Easier for Americans with Multiple Sclerosis to Access Neurotech that can Improve their Ability to Walk

January 3, 2023

Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

December 30, 2022

Helius Medical Technologies, Inc. Reports Third Quarter 2022 Financial Results

November 14, 2022

Helius Medical Technologies, Inc. Announces Participation of Dr. Prue Plummer and MGH Institute of Health Professions to its Therapeutic Experience Program

November 9, 2022

Helius Medical Technologies, Inc. Announces Participation of Oregon Health & Science University in its Therapeutic Experience Program

November 8, 2022

Helius to Showcase Innovative PoNS Device at ACRM’s 2022 Conference – Demonstrating the Power of Neuromodulation to Help People with MS Improve their Gait

November 3, 2022

Helius Medical Technologies, Inc. to Release Third Quarter 2022 Financial Results on November 14, 2022

November 1, 2022

Helius Salutes Physical Therapists for Their Role in Helping People with MS Improve Their Gait

October 13, 2022

Helius Medical Technologies to Present at the ROTH Capital Partners Inaugural Healthcare Opportunities Conference

September 29, 2022

Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

September 14, 2022

Helius Medical Technologies to Present at Upcoming Healthcare Investor Conferences in September

September 6, 2022

Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 17, 2022

Helius Medical Technologies, Inc. Reports Second Quarter 2022 Financial Results

August 15, 2022

Helius Medical Technologies, Inc. to Release Second Quarter 2022 Financial Results on August 15, 2022

August 10, 2022

Helius Medical Technologies, Inc. Announces Pricing of $18 Million Public Offering

August 5, 2022

Helius Medical Technologies, Inc. Announces Online Training for PoNS Therapy™

July 12, 2022

Helius Medical Technologies, Inc. Presents Poster at the 2022 Consortium of Multiple Sclerosis Centers (“CMSC”) Annual Meetin

June 6, 2022

Helius Medical Technologies, Inc. Announces Launch of Patient Therapy Access Program for PoNS®

June 1, 2022

Helius Medical Announces Poster to Be Presented at the Consortium for Multiple Sclerosis Centers (CMSC) Annual Conference

May 31, 2022

Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

May 24, 2022

Helius Medical Technologies, Inc. Announces Participation of Dr. Deborah Backus and Shepherd Center in its Therapeutic Experience Program

May 17, 2022

Helius Medical Technologies, Inc. Reports First Quarter 2022 Financial Results and Provides Update on U.S. Commercial Launch of PoNS®

May 12, 2022

Helius Medical Technologies, Inc. to Release First Quarter 2022 Financial Results on May 12, 2022

May 3, 2022

Helius Medical Technologies, Inc. Fulfills First U.S. Prescriptions for PoNS®

April 27, 2022

Helius Medical Technologies, Inc. Introduces Device in U.S. To Help Multiple Sclerosis Patients Improve Walking Ability

April 26, 2022

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results

March 14, 2022

Helius Medical Technologies, Inc. Provides Corporate Update

January 26, 2022

Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 20, 2021

Helius Medical Technologies, Inc. Partners with the Medical University of South Carolina in Pilot Trial on Stroke

December 17, 2021

Helius Medical Technologies, Inc. Announces Issuance of U.S. Patent for Wireless PoNS®

December 14, 2021

Helius Medical Technologies, Inc.’s Dr. Antonella Favit-Van Pelt to Present at 4th International Brain Stimulation Conference on December 9

December 6, 2021

Helius Medical Technologies, Inc. to Participate in 1x1 Meetings at 12th Annual Craig-Hallum Alpha Select Conference on November 16, 2021

November 15, 2021

Helius Medical Technologies, Inc. Announces Closing of $11.1 Million Underwritten Public Offering of Common Stock Including Full Exercise of Over-Allotment Option

November 12, 2021

Helius Medical Technologies, Inc. Reports Third Quarter 2021 Financial Results

November 10, 2021

Helius Medical Technologies, Inc. Announces Pricing of $9.6 Million Underwritten Public Offering of Common Stock

November 10, 2021

Helius Medical Technologies, Inc. Announces Proposed Underwritten Public Offering of Common Stock

November 9, 2021

Helius Medical Technologies, Inc. Launches Therapeutic Experience Program; NYU Langone Health Is Initial Clinical Trial Site

November 8, 2021

Helius Medical Technologies, Inc. Receives PoNS® Market Authorization in Australia

November 4, 2021

Helius Medical Technologies, Inc. to Release Third Quarter 2021 Financial Results on November 10, 2021

November 1, 2021

Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

October 29, 2021

Helius Medical Technologies, Inc. to Present at the Dawson James Small Cap Growth Conference

October 12, 2021

Helius Medical Technologies, Inc. to Present at the Benzinga Healthcare Small Cap Conference

September 22, 2021

Helius Medical Technologies, Inc. Appoints Paul Buckman to its Board of Directors

September 14, 2021

Helius Medical Technologies, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 7, 2021

Helius Medical Technologies, Inc. Announces Voluntary De-Listing from Toronto Stock Exchange

August 25, 2021

Helius Medical Technologies, Inc. Announces FDA Breakthrough Device Designation for the Treatment of Dynamic Gait and Balance Deficits Following a Stroke

August 17, 2021

Helius Medical Technologies, Inc. Reports Second Quarter 2021 Financial Results

August 12, 2021

Helius Medical Technologies, Inc. Launches New Website for U.S.-Based Patients and Physicians

August 11, 2021

Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 11, 2021

Helius Medical Technologies, Inc. to Present at Two Upcoming Investor Conferences in July

July 12, 2021

Helius Medical Technologies, Inc. Appoints Antonella Favit-Van Pelt, M.D., Ph.D. as Chief Medical Officer

July 8, 2021

Helius Medical Technologies, Inc. to Participate in the Annual World Congress of the Society for Brain Mapping and Therapeutics

July 7, 2021

Helius Medical Technologies, Inc. to Release Second Quarter of Fiscal Year 2021 Financial Results on August 12, 2021

June 30, 2021

Helius Medical Technologies, Inc. Expands Executive Leadership Team with the Appointment of Dane C. Andreeff as President and Chief Executive Officer and Jeffrey S. Mathiesen as Chief Financial Officer

June 15, 2021

Helius Medical Technologies, Inc. to Participate in Noble Capital Markets’ Virtual Road Show Series

June 8, 2021

Helius Medical Technologies, Inc. Appoints Frederick Fantazzia as Vice President of Sales & Marketing, North America

June 2, 2021

Helius Medical Technologies, Inc. Reports First Quarter 2021 Financial Results

May 17, 2021

Helius Medical Technologies, Inc. to Present at the Planet MicroCap Showcase on April 21st

April 15, 2021

Helius Medical Technologies, Inc. to Release First Quarter of Fiscal Year 2021 Financial Results on May 17, 2021

April 7, 2021

Helius Medical, Inc Receives U.S. Marketing Authorization for the PoNS™ Device

March 29, 2021

Helius Medical Technologies, Inc. Appoints Sherrie Perkins to its Board of Directors

March 17, 2021

Helius Medical Technologies, Inc. to Present at the Investor Summit Group’s Q1 Virtual Summit on March 23rd

March 17, 2021

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results

March 10, 2021

Helius Medical Technologies to Release Fourth Quarter and Fiscal Year 2020 Financial Results on March 10, 2021

February 2, 2021

Helius Medical Technologies, Inc. Announces Closing of $11.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

February 1, 2021

Helius Medical Technologies, Inc. Announces Pricing of $9.6 Million Underwritten Public Offering Priced At Market

January 28, 2021

Helius Medical Technologies, Inc. Comments on the Centers for Medicare & Medicaid Services’ Announcement Regarding New Medicare Coverage Pathway for Breakthrough Medical Devices

January 20, 2021

Helius Medical Technologies, Inc. Regains Compliance with Nasdaq Listing Standards

January 19, 2021

Helius Medical Technologies, Inc. to Present at the Noble Capital Markets 17th Annual Small & Microcap Investor Conference

January 15, 2021

Helius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the PoNS™ Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis

January 11, 2021

Helius Medical Technologies, Inc. Comments on Unusual Market Activity

January 5, 2021

Helius Medical Technologies, Inc. to Present at Four Upcoming Investor Conferences in January

January 4, 2021

Helius Medical Technologies, Inc. Announces Reverse Stock Split

December 31, 2020

Helius Medical Technologies, Inc. Reports Third Quarter of Fiscal Year 2020 Financial Results

November 12, 2020

Helius Medical Technologies, Inc. to Present at Upcoming Investor Conferences in November

November 5, 2020

Helius Medical Technologies, Inc. Announces the Expansion to a Total of 27 Authorized PoNS Treatment™ Clinic Locations Across Canada

November 4, 2020

Helius Medical Technologies to Release Third Quarter of Fiscal Year 2020 Financial Results on November 12, 2020

November 2, 2020

Helius Medical Technologies Announces Closing of $3.4 Million Private Placement

October 26, 2020

Helius Medical Technologies, Inc. Provides Update on FDA’s Review of its Request for De Novo Classification and Clearance of the PoNS™ Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis

October 19, 2020

Helius Medical Technologies, Inc. Announces Partnership with Breakthrough Health for Multiple Sclerosis Insights

October 14, 2020

Helius Medical Technologies, Inc. Announces Formation of Multiple Sclerosis Scientific Advisory Board

October 8, 2020

Helius Medical Technologies, Inc. Announces Publication of Peer-Reviewed Study: Translingual Neural Stimulation with the Portable Neuromodulation Stimulator (PoNS™) Induces Structural Changes Leading to Functional Recovery in Patients with Mild-to-Moderate Traumatic Brain Injury

September 8, 2020

Helius Medical Technologies, Inc. to Present at Three Upcoming Investor Conferences in September

August 31, 2020

Helius Medical Technologies, Inc. Announces Departure of President, Chief Executive Officer and Chairman Philippe Deschamps; Board of Directors Appoints Dane C. Andreeff as Interim President and Chief Executive Officer and Appoints Blane Walter as Chairman of the Board of Directors

August 25, 2020

Helius Medical Technologies, Inc. Reports Second Quarter of Fiscal Year 2020 Financial Results

August 12, 2020

Helius Medical Technologies to Release Second Quarter of Fiscal Year 2020 Financial Results on August 12, 2020

August 10, 2020

Helius Medical Technologies, Inc. Submits Request for FDA Clearance for PoNS™ Device; Reports Preliminary Financial Results for the Second Quarter and Six Months Ended June 30, 2020

August 6, 2020

Helius Medical Technologies Announces the Dismissal of the Shareholder Class Action Lawsuit

July 14, 2020

Helius Medical Technologies to Present at the Virtual Summer Summit on June 9th

June 5, 2020

Helius Medical Technologies, Inc. Announces FDA Has Granted the PoNS Device Breakthrough Device Designation for the Treatment of Gait Deficits Due to Symptoms of Multiple Sclerosis

May 12, 2020